PREMMi, Pôle de Recherche et d'Enseignement en Médecine Mitochondriale, Institut MITOVASC, CNRS 6214, INSERM U1083, Université d'Angers , 4 Rue Larrey, 49933 Angers CEDEX 9, France.
Département de Biochimie et Génétique, Centre Hospitalier Universitaire , 49933 Angers CEDEX 9, France.
Anal Chem. 2017 Feb 7;89(3):2138-2146. doi: 10.1021/acs.analchem.6b04912. Epub 2017 Jan 6.
In recent years, the number of investigations based on nontargeted metabolomics has increased, although often without a thorough assessment of analytical strategies applied to acquire data. Following published guidelines for metabolomics experiments, we report a validated nontargeted metabolomics strategy with pipeline for unequivocal identification of metabolites using the MSMLS molecule library. We achieved an in-house database containing accurate m/z values, retention times, isotopic patterns, full MS, and MS/MS spectra. A UHPLC-HRMS Q-Exactive method was developed, and experimental variations were determined within and between 3 experimental days. The extraction efficiency as well as the accuracy, precision, repeatability, and linearity of the method were assessed, the method demonstrating good performances. The methodology was further blindly applied to plasma from remote ischemic pre-conditioning (RIPC) rats. Samples, previously analyzed by targeted metabolomics using completely different protocol, analytical strategy, and platform, were submitted to our analytical pipeline. A combination of multivariate and univariate statistical analyses was employed. Selection of putative biomarkers from OPLS-DA model and S-plot was combined to jack-knife confidence intervals, metabolites' VIP values, and univariate statistics. Only variables with strong model contribution and highly statistical reliability were selected as discriminated metabolites. Three biomarkers identified by the previous targeted metabolomics study were found in the current work, in addition to three novel metabolites, emphasizing the efficiency of the current methodology and its ability to identify new biomarkers of clinical interest, in a single sequence. The biomarkers were identified to level 1 according to the metabolomics standard initiative and confirmed by both RPLC and HILIC-HRMS.
近年来,基于非靶向代谢组学的研究数量有所增加,尽管通常没有对用于获取数据的分析策略进行彻底评估。我们根据代谢组学实验的已发表指南,报告了一种经过验证的非靶向代谢组学策略,该策略使用 MSMLS 分子库提供了用于明确鉴定代谢物的管道。我们建立了一个内部数据库,其中包含准确的 m/z 值、保留时间、同位素模式、全 MS 和 MS/MS 谱。开发了 UHPLC-HRMS Q-Exactive 方法,并在 3 个实验日内确定了实验内和实验间的变化。评估了该方法的提取效率以及准确性、精密度、重复性和线性,该方法表现出良好的性能。该方法学进一步被盲目应用于远程缺血预处理(RIPC)大鼠的血浆中。先前使用完全不同的方案、分析策略和平台进行靶向代谢组学分析的样品,被提交给我们的分析管道。采用多元和单变量统计分析相结合的方法。从 OPLS-DA 模型和 S-plot 中选择假定的生物标志物,结合 Jack-knife 置信区间、代谢物的 VIP 值和单变量统计,进行分析。只有具有强模型贡献和高度统计可靠性的变量才被选为有区别的代谢物。除了之前靶向代谢组学研究中发现的 3 种生物标志物外,当前工作还发现了 3 种新的代谢物,这强调了当前方法学的效率及其在单个序列中识别临床感兴趣的新生物标志物的能力。根据代谢组学标准倡议,将这些生物标志物鉴定到 1 级,并通过 RPLC 和 HILIC-HRMS 进行确认。